157 related articles for article (PubMed ID: 37410264)
1. Impact of non-regional lymph node metastases accurately revealed on
Jiang Z; Fan J; Gan C; Dong X; Gao G; Wang Z; He D; Li L; Duan X; Wu K
EJNMMI Res; 2023 Jul; 13(1):64. PubMed ID: 37410264
[TBL] [Abstract][Full Text] [Related]
2. Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
Heesterman BL; van der Poel HG; Schoots IG; Mehra N; Aben KKH
BJU Int; 2022 Aug; 130(2):217-225. PubMed ID: 34741789
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging.
Onal C; Guler OC; Erpolat P; Hurmuz P; Sutera P; Deek MP; Elmali A; Yilmaz MT; Koken UH; Yavuz M; Ozyigit G; Tran PT
Clin Nucl Med; 2024 Jun; ():. PubMed ID: 38847441
[TBL] [Abstract][Full Text] [Related]
5. Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
Ali A; Hoyle A; Mistry H; Clarke NW
BJU Int; 2019 Jan; 123(1):65-73. PubMed ID: 29777564
[TBL] [Abstract][Full Text] [Related]
6. The Prognostic Value of Posttreatment
Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
[No Abstract] [Full Text] [Related]
7. PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
Bianchi L; Ceci F; Balestrazzi E; Costa F; Droghetti M; Piazza P; Pissavini A; Presutti M; Farolfi A; Mei R; Castellucci P; Gandaglia G; Larcher A; Robesti D; Mottrie A; Briganti A; Morganti AG; Fanti S; Montorsi F; Schiavina R; Brunocilla E
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046687
[TBL] [Abstract][Full Text] [Related]
8. Detection Efficacy of
Giesel FL; Knorr K; Spohn F; Will L; Maurer T; Flechsig P; Neels O; Schiller K; Amaral H; Weber WA; Haberkorn U; Schwaiger M; Kratochwil C; Choyke P; Kramer V; Kopka K; Eiber M
J Nucl Med; 2019 Mar; 60(3):362-368. PubMed ID: 30042163
[TBL] [Abstract][Full Text] [Related]
9. Mesorectal Lymph Node Metastases as Index Lesion in
Leitsmann C; Schmid M; Sahlmann CO; Trojan L; Strauss A
Front Surg; 2021; 8():637134. PubMed ID: 33732729
[No Abstract] [Full Text] [Related]
10. Comparison of
Walacides D; Meier A; Knöchelmann AC; Meinecke D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; von Klot CAJ; Christiansen H; Henkenberens C
Strahlenther Onkol; 2019 May; 195(5):420-429. PubMed ID: 30610354
[TBL] [Abstract][Full Text] [Related]
11. Progression-free survival in patients with
Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM
Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648
[TBL] [Abstract][Full Text] [Related]
12. Risk of metastatic disease using [
Chikatamarla VA; Okano S; Jenvey P; Ansaldo A; Roberts MJ; Ramsay SC; Thomas PA; Pattison DA
EJNMMI Res; 2021 Dec; 11(1):128. PubMed ID: 34928437
[TBL] [Abstract][Full Text] [Related]
13. Assessing the accuracy of [
Ingvar J; Hvittfeldt E; Trägårdh E; Simoulis A; Bjartell A
EJNMMI Res; 2022 Aug; 12(1):48. PubMed ID: 35943665
[TBL] [Abstract][Full Text] [Related]
14. Regional location of lymph node metastases predicts survival in patients with
Wang ZP; Chen JR; Zhao JG; Zhu S; Zhang XM; Liang JY; He B; Ni YC; Sun GX; Shen PF; Zeng H
Asian J Androl; 2023; 25(4):462-467. PubMed ID: 36348577
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous uptake of
Hu Y; Wang P; Dai W
BMC Pulm Med; 2023 Mar; 23(1):73. PubMed ID: 36882747
[TBL] [Abstract][Full Text] [Related]
16. High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation.
Rahman LA; Rutagengwa D; Lin P; Lin M; Yap J; Lai K; Mancuso P; Rathore P; Haghighi K; Gassner P; Wong LH; Lalak N
Cancer Imaging; 2019 Dec; 19(1):86. PubMed ID: 31829288
[TBL] [Abstract][Full Text] [Related]
17. A prospective, multicenter head-to-head comparative study in patients with primary high-risk prostate cancer investigating the bone lesion detection of conventional imaging and
Bodar YJL; Luining WI; Keizer B; Meijer D; Vellekoop A; Schaaf M; Hendrikse NH; Van Moorselaar RJA; Oprea-Lager DE; Vis AN
Urol Oncol; 2023 Apr; 41(4):205.e17-205.e24. PubMed ID: 36588019
[TBL] [Abstract][Full Text] [Related]
18. The Establishment of New Thresholds for PLND-Validated Clinical Nomograms to Predict Non-Regional Lymph Node Metastases: Using
Jiao J; Quan Z; Zhang J; Wen W; Qin J; Yang L; Meng P; Jing Y; Ma S; Wu P; Han D; Davis AA; Ren J; Yang X; Kang F; Zhang Q; Wang J; Qin W
Front Oncol; 2021; 11():658669. PubMed ID: 33937073
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With
Spohn SKB; Birkenmaier V; Ruf J; Mix M; Sigle A; Haehl E; Adebahr S; Sprave T; Gkika E; Rühle A; Nicolay NH; Kirste S; Grosu AL; Zamboglou C
Front Oncol; 2022; 12():898774. PubMed ID: 35747822
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
Sabet A; Binse I; Grafe H; Ezziddin S; Görges R; Poeppel TD; Bockisch A; Rosenbaum-Krumme SJ
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
